• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2020-2026

report cover
  • 31 July 2020
  • Pharmaceuticals
  • 97 Pages
  • Report Code: 24LS-16396
  • Formate :   
Download FREE Report Sample Download PDF File

HER2 negative breast cancer Treatment -MARKET ADVISORY SERVICES

HER2-negative breast cancer Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global HER2-negative breast cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Pfizer
Novartis
Pfizer
GlaxoSmithKline
Novartis
Merck
Eli Lilly

Market segment by Type, the product can be split into
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy
Market segment by Application, split into
Hosptial
Clinic

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by HER2-negative breast cancer Treatment Revenue
1.4 Market by Type
1.4.1 Global HER2-negative breast cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Surgery
1.4.4 Radiation
1.4.5 Hormonal therapy/endocrine therapy
1.5 Market by Application
1.5.1 Global HER2-negative breast cancer Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hosptial
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global HER2-negative breast cancer Treatment Market Perspective (2015-2026)
2.2 Global HER2-negative breast cancer Treatment Growth Trends by Regions
2.2.1 HER2-negative breast cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 HER2-negative breast cancer Treatment Historic Market Share by Regions (2015-2020)
2.2.3 HER2-negative breast cancer Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 HER2-negative breast cancer Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key HER2-negative breast cancer Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top HER2-negative breast cancer Treatment Players by Market Size
3.1.1 Global Top HER2-negative breast cancer Treatment Players by Revenue (2015-2020)
3.1.2 Global HER2-negative breast cancer Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global HER2-negative breast cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global HER2-negative breast cancer Treatment Market Concentration Ratio
3.2.1 Global HER2-negative breast cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by HER2-negative breast cancer Treatment Revenue in 2019
3.3 HER2-negative breast cancer Treatment Key Players Head office and Area Served
3.4 Key Players HER2-negative breast cancer Treatment Product Solution and Service
3.5 Date of Enter into HER2-negative breast cancer Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global HER2-negative breast cancer Treatment Historic Market Size by Type (2015-2020)
4.2 Global HER2-negative breast cancer Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global HER2-negative breast cancer Treatment Market Size by Application (2015-2020)
5.2 Global HER2-negative breast cancer Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America HER2-negative breast cancer Treatment Market Size (2015-2020)
6.2 HER2-negative breast cancer Treatment Key Players in North America (2019-2020)
6.3 North America HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
6.4 North America HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe HER2-negative breast cancer Treatment Market Size (2015-2020)
7.2 HER2-negative breast cancer Treatment Key Players in Europe (2019-2020)
7.3 Europe HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
7.4 Europe HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

8 China
8.1 China HER2-negative breast cancer Treatment Market Size (2015-2020)
8.2 HER2-negative breast cancer Treatment Key Players in China (2019-2020)
8.3 China HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
8.4 China HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan HER2-negative breast cancer Treatment Market Size (2015-2020)
9.2 HER2-negative breast cancer Treatment Key Players in Japan (2019-2020)
9.3 Japan HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
9.4 Japan HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia HER2-negative breast cancer Treatment Market Size (2015-2020)
10.2 HER2-negative breast cancer Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

11 India
11.1 India HER2-negative breast cancer Treatment Market Size (2015-2020)
11.2 HER2-negative breast cancer Treatment Key Players in India (2019-2020)
11.3 India HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
11.4 India HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America HER2-negative breast cancer Treatment Market Size (2015-2020)
12.2 HER2-negative breast cancer Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America HER2-negative breast cancer Treatment Market Size by Type (2015-2020)
12.4 Central & South America HER2-negative breast cancer Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca HER2-negative breast cancer Treatment Introduction
13.1.4 AstraZeneca Revenue in HER2-negative breast cancer Treatment Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb HER2-negative breast cancer Treatment Introduction
13.2.4 Bristol-Myers Squibb Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly HER2-negative breast cancer Treatment Introduction
13.3.4 Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer HER2-negative breast cancer Treatment Introduction
13.4.4 Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis HER2-negative breast cancer Treatment Introduction
13.5.4 Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer HER2-negative breast cancer Treatment Introduction
13.6.4 Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 GlaxoSmithKline
13.7.1 GlaxoSmithKline Company Details
13.7.2 GlaxoSmithKline Business Overview
13.7.3 GlaxoSmithKline HER2-negative breast cancer Treatment Introduction
13.7.4 GlaxoSmithKline Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.7.5 GlaxoSmithKline Recent Development
13.8 Novartis
13.8.1 Novartis Company Details
13.8.2 Novartis Business Overview
13.8.3 Novartis HER2-negative breast cancer Treatment Introduction
13.8.4 Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.8.5 Novartis Recent Development
13.9 Merck
13.9.1 Merck Company Details
13.9.2 Merck Business Overview
13.9.3 Merck HER2-negative breast cancer Treatment Introduction
13.9.4 Merck Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.9.5 Merck Recent Development
13.10 Eli Lilly
13.10.1 Eli Lilly Company Details
13.10.2 Eli Lilly Business Overview
13.10.3 Eli Lilly HER2-negative breast cancer Treatment Introduction
13.10.4 Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020)
13.10.5 Eli Lilly Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Tables

Table 1. HER2-negative breast cancer Treatment Key Market Segments

Table 2. Key Players Covered: Ranking by HER2-negative breast cancer Treatment Revenue

Table 3. Ranking of Global Top HER2-negative breast cancer Treatment Manufacturers by Revenue (US$ Million) in 2019

Table 4. Global HER2-negative breast cancer Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026

Table 5. Key Players of Chemotherapy

Table 6. Key Players of Surgery

Table 7. Key Players of Radiation

Table 8. Key Players of Hormonal therapy/endocrine therapy

Table 9. Global HER2-negative breast cancer Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026

Table 10. Global HER2-negative breast cancer Treatment Market Size by Regions (US$ Million): 2020 VS 2026

Table 11. Global HER2-negative breast cancer Treatment Market Size by Regions (2015-2020) (US$ Million)

Table 12. Global HER2-negative breast cancer Treatment Market Share by Regions (2015-2020)

Table 13. Global HER2-negative breast cancer Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)

Table 14. Global HER2-negative breast cancer Treatment Market Share by Regions (2021-2026)

Table 15. Market Top Trends

Table 16. Key Drivers: Impact Analysis

Table 17. Key Challenges

Table 18. HER2-negative breast cancer Treatment Market Growth Strategy

Table 19. Main Points Interviewed from Key HER2-negative breast cancer Treatment Players

Table 20. Global HER2-negative breast cancer Treatment Revenue by Players (2015-2020) (Million US$)

Table 21. Global HER2-negative breast cancer Treatment Market Share by Players (2015-2020)

Table 22. Global Top HER2-negative breast cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-negative breast cancer Treatment as of 2019)

Table 23. Global HER2-negative breast cancer Treatment by Players Market Concentration Ratio (CR5 and HHI)

Table 24. Key Players Headquarters and Area Served

Table 25. Key Players HER2-negative breast cancer Treatment Product Solution and Service

Table 26. Date of Enter into HER2-negative breast cancer Treatment Market

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 29. Global HER2-negative breast cancer Treatment Market Size Share by Type (2015-2020)

Table 30. Global HER2-negative breast cancer Treatment Revenue Market Share by Type (2021-2026)

Table 31. Global HER2-negative breast cancer Treatment Market Size Share by Application (2015-2020)

Table 32. Global HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 33. Global HER2-negative breast cancer Treatment Market Size Share by Application (2021-2026)

Table 34. North America Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)

Table 35. North America Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)

Table 36. North America HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 37. North America HER2-negative breast cancer Treatment Market Share by Type (2015-2020)

Table 38. North America HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 39. North America HER2-negative breast cancer Treatment Market Share by Application (2015-2020)

Table 40. Europe Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)

Table 41. Europe Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)

Table 42. Europe HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 43. Europe HER2-negative breast cancer Treatment Market Share by Type (2015-2020)

Table 44. Europe HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 45. Europe HER2-negative breast cancer Treatment Market Share by Application (2015-2020)

Table 46. China Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)

Table 47. China Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)

Table 48. China HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 49. China HER2-negative breast cancer Treatment Market Share by Type (2015-2020)

Table 50. China HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 51. China HER2-negative breast cancer Treatment Market Share by Application (2015-2020)

Table 52. Japan Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)

Table 53. Japan Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)

Table 54. Japan HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 55. Japan HER2-negative breast cancer Treatment Market Share by Type (2015-2020)

Table 56. Japan HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 57. Japan HER2-negative breast cancer Treatment Market Share by Application (2015-2020)

Table 58. Southeast Asia Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)

Table 59. Southeast Asia Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)

Table 60. Southeast Asia HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 61. Southeast Asia HER2-negative breast cancer Treatment Market Share by Type (2015-2020)

Table 62. Southeast Asia HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 63. Southeast Asia HER2-negative breast cancer Treatment Market Share by Application (2015-2020)

Table 64. India Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)

Table 65. India Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)

Table 66. India HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 67. India HER2-negative breast cancer Treatment Market Share by Type (2015-2020)

Table 68. India HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 69. India HER2-negative breast cancer Treatment Market Share by Application (2015-2020)

Table 70. Central & South America Key Players HER2-negative breast cancer Treatment Revenue (2019-2020) (Million US$)

Table 71. Central & South America Key Players HER2-negative breast cancer Treatment Market Share (2019-2020)

Table 72. Central & South America HER2-negative breast cancer Treatment Market Size by Type (2015-2020) (Million US$)

Table 73. Central & South America HER2-negative breast cancer Treatment Market Share by Type (2015-2020)

Table 74. Central & South America HER2-negative breast cancer Treatment Market Size by Application (2015-2020) (Million US$)

Table 75. Central & South America HER2-negative breast cancer Treatment Market Share by Application (2015-2020)

Table 76. AstraZeneca Company Details

Table 77. AstraZeneca Business Overview

Table 78. AstraZeneca Product

Table 79. AstraZeneca Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 80. AstraZeneca Recent Development

Table 81. Bristol-Myers Squibb Company Details

Table 82. Bristol-Myers Squibb Business Overview

Table 83. Bristol-Myers Squibb Product

Table 84. Bristol-Myers Squibb Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 85. Bristol-Myers Squibb Recent Development

Table 86. Eli Lilly Company Details

Table 87. Eli Lilly Business Overview

Table 88. Eli Lilly Product

Table 89. Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 90. Eli Lilly Recent Development

Table 91. Pfizer Company Details

Table 92. Pfizer Business Overview

Table 93. Pfizer Product

Table 94. Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 95. Pfizer Recent Development

Table 96. Novartis Company Details

Table 97. Novartis Business Overview

Table 98. Novartis Product

Table 99. Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 100. Novartis Recent Development

Table 101. Pfizer Company Details

Table 102. Pfizer Business Overview

Table 103. Pfizer Product

Table 104. Pfizer Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 105. Pfizer Recent Development

Table 106. GlaxoSmithKline Company Details

Table 107. GlaxoSmithKline Business Overview

Table 108. GlaxoSmithKline Product

Table 109. GlaxoSmithKline Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 110. GlaxoSmithKline Recent Development

Table 111. Novartis Business Overview

Table 112. Novartis Product

Table 113. Novartis Company Details

Table 114. Novartis Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 115. Novartis Recent Development

Table 116. Merck Company Details

Table 117. Merck Business Overview

Table 118. Merck Product

Table 119. Merck Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 120. Merck Recent Development

Table 121. Eli Lilly Company Details

Table 122. Eli Lilly Business Overview

Table 123. Eli Lilly Product

Table 124. Eli Lilly Revenue in HER2-negative breast cancer Treatment Business (2015-2020) (Million US$)

Table 125. Eli Lilly Recent Development

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

List of Figures

Figure 1. Global HER2-negative breast cancer Treatment Market Share by Type: 2020 VS 2026

Figure 2. Chemotherapy Features

Figure 3. Surgery Features

Figure 4. Radiation Features

Figure 5. Hormonal therapy/endocrine therapy Features

Figure 6. Global HER2-negative breast cancer Treatment Market Share by Application: 2020 VS 2026

Figure 7. Hosptial Case Studies

Figure 8. Clinic Case Studies

Figure 9. HER2-negative breast cancer Treatment Report Years Considered

Figure 10. Global HER2-negative breast cancer Treatment Market Size YoY Growth 2015-2026 (US$ Million)

Figure 11. Global HER2-negative breast cancer Treatment Market Share by Regions: 2020 VS 2026

Figure 12. Global HER2-negative breast cancer Treatment Market Share by Regions (2021-2026)

Figure 13. Porter's Five Forces Analysis

Figure 14. Global HER2-negative breast cancer Treatment Market Share by Players in 2019

Figure 15. Global Top HER2-negative breast cancer Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-negative breast cancer Treatment as of 2019

Figure 16. The Top 10 and 5 Players Market Share by HER2-negative breast cancer Treatment Revenue in 2019

Figure 17. North America HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 18. Europe HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 19. China HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 20. Japan HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 21. Southeast Asia HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 22. India HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 23. Central & South America HER2-negative breast cancer Treatment Market Size YoY Growth (2015-2020) (Million US$)

Figure 24. Bottom-up and Top-down Approaches for This Report

Figure 25. Data Triangulation

Figure 26. Key Executives Interviewed

AstraZeneca

Bristol-Myers Squibb

Eli Lilly

Pfizer

Novartis

Pfizer

GlaxoSmithKline

Novartis

Merck

Eli Lilly

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $3042

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase